Necrotising soft-tissue infections

C Hua, T Urbina, R Bosc, T Parks… - The Lancet Infectious …, 2023 - thelancet.com
The incidence of necrotising soft-tissue infections has increased during recent decades such
that most physicians might see at least one case of these potentially life-threatening …

[HTML][HTML] Necrotizing skin and soft-tissue infections in the intensive care unit

M Peetermans, N de Prost, C Eckmann… - Clinical Microbiology …, 2020 - Elsevier
Background Necrotizing skin and soft-tissue infections (NSTI) are rare but potentially life-
threatening and disabling infections that often require intensive care unit admission …

Key takeaways from the US CDC's 2019 antibiotic resistance threats report for frontline providers

SS Kadri - Critical care medicine, 2020 - journals.lww.com
At 2.8 million infections due to AR pathogens and 35,900 attributable deaths each year (2),
AR is still a very real problem in the United States. Given that sicker patients not only tend to …

Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective …

A Babiker, X Li, YL Lai, JR Strich, S Warner… - The Lancet Infectious …, 2021 - thelancet.com
Background Clindamycin is strongly recommended as an adjunctive treatment to β-lactam
antibiotics in patients with severe invasive group A β-haemolytic streptococcal (iGAS) …

Should linezolid replace clindamycin as the adjunctive antimicrobial of choice in group A streptococcal necrotizing soft tissue infection and toxic shock syndrome? A …

N Cortés-Penfield, JH Ryder - Clinical Infectious Diseases, 2023 - academic.oup.com
Abstract Group A Streptococcus (GAS) necrotizing soft tissue infections and toxic shock
syndrome remain high-mortality conditions. In vitro and animal model data, as well as …

Antibiotic Treatment, Mechanisms for Failure, and Adjunctive Therapies for Infections by Group A Streptococcus

AF Johnson, CN LaRock - Frontiers in microbiology, 2021 - frontiersin.org
Group A Streptococcus (GAS; Streptococcus pyogenes) is a nearly ubiquitous human
pathogen responsible for a significant global disease burden. No vaccine exists, so …

Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France

B Lefèvre, L Tondeur, Y Madec, R Grant… - The Lancet Healthy …, 2021 - thelancet.com
Variants of SARS-CoV-2 have emerged that are more transmissible than the original virus or
that exhibit some properties of immune escape, or both. The beta (B. 1.351) variant has …

Patterns of Antibiotic Nonsusceptibility Among Invasive Group A Streptococcus Infections—United States, 2006–2017

K Fay, J Onukwube, S Chochua… - Clinical Infectious …, 2021 - academic.oup.com
Background Treatment of severe group A Streptococcus (GAS) infections requires timely
and appropriate antibiotic therapy. We describe the epidemiology of antimicrobial-resistant …

[HTML][HTML] Time to negative throat culture following initiation of antibiotics for pharyngeal group A Streptococcus: a systematic review and meta-analysis up to October …

E McGuire, A Li, SM Collin, V Decraene… - …, 2023 - eurosurveillance.org
Background Public health guidance recommending isolation of individuals with group A
streptococcal (GAS) infection or carriage for 12–24 h from antibiotic initiation to prevent …

Antibiotics in necrotizing soft tissue infections

T Urbina, K Razazi, C Ourghanlian, PL Woerther… - Antibiotics, 2021 - mdpi.com
Necrotizing soft tissue infections (NSTIs) are rare life-threatening bacterial infections
characterized by an extensive necrosis of skin and subcutaneous tissues. Initial urgent …